From: Mechanism of drug-induced liver injury and hepatoprotective effects of natural drugs
No. | Natural medicine | Bioactive components | Mechanisms | The species investigated | References |
---|---|---|---|---|---|
1 | Fucus vesiculosus | Polysaccharide | Inhibits the overexpression of CYP2E1 and reduces apoptosis caused by Bax, Bcl-2 and caspase-3. Anti-oxidant and anti-inflammatory | Pre-clinical model: Male SD rats(6-week-old) | [102] |
2 | Schisandra chinensis (Turcz) Baill | Polysaccharide | Up-regulate GSH and Nrf2, reduce the level of MDA. Anti-oxidant | Pre-clinical model: Male ICR mice (20–23 g) | [103] |
3 | Artemisia argyi Levl.et Vant | Polysaccharide | Increased blood glucose concentration indicators, hepatocyte protection | Pre-clinical model: Healthy adult rabbit | [104] |
4 | Millettia pulchra Kurz var-laxior (Dunn) Z.Wei | Polysaccharide | Attenuating free radical injury and inhibiting lipid peroxidation and lowering release of inflammatory factors; Reduce liver damage and activate the anti-oxidant defense system | Pre-clinical model: Healthy Kunming mice, half male and half male (18–20 g); Kunming SPF mice, half male and half male (18–20 g); Kunming SPF mice (18–20 g) | |
5 | Angelica sinensis (Oliv.) Diels | Polysaccharide | Anti-oxidative | Pre-clinical model: Male ICR mice (35–40 g) and SD rats (120–150 g) | [92] |
6 | Sophorae tonkinensis Radix (S. tonkinensis) | Polysaccharide | Anti-oxidative | Pre-clinical model: Male ICR mice (25–30 g) | [108] |
7 | Sargassum | polysaccharide | Anti-oxidative, anti-inflammatory, and anti-apoptotic | Pre-clinical model: Male SD rats | [109] |
8 | Sargassum polycystum | Polysaccharide | Confirmed the effectiveness of the crude polysaccharide against acetaminophen-induced abnormality in rats | Pre-clinical model: Male albino Wistar rats (120–150 g) | [110] |
9 | Aureobasidium sp. | β-glucan | The increase of ALT and AST has a significant inhibitory effect | Pre-clinical model: Specific pathogen-free Balb/c mice (6–7 weeks) | [111] |
10 | Sagittaria sagittifolia L | Polysaccharides | Activation of NRF2 and its target antioxidant enzymes and inhibition of the expression of CYPs | Pre-clinical model: Sixty male BALB/c mice (18–22 g) | [112] |
11 | Dicliptera Chinensis (L.)Nees | Polysaccharide | Anti-inflammatory | Pre-clinical model: 60 SPF Kunming mice, (18–22 g), half male and half female | [113] |
12 | Mangifera indica L | Polysaccharide | Anti-oxidative | Pre-clinical model: Adult male albino Wistar rats (145–155 g) | [114] |
13 | M. chinensis Maxim cv. jiangxiangru | The Polysaccharide contains 11% uronic acid and 9% protein, and the polysaccharide part contains rhamnose, ara It is composed of primary sugar, mannose, glucose and galactose, and the molar ratio of monosaccharides is 5.3: 12.3: 3.4: 12.2: 32.6: 30.6 | Anti-oxidative | Pre-clinical model: KM mice (8 weeks old, 20 ± 2 g) | [115] |
14 | Polygonum Cillinerve (Nakai) Ohwi | Polysaccharide | Anti-oxidative | Pre-clinical model: ICR mice (8 weeks old, 20 ± 2 g) | [116] |
15 | Atractylodes macrocephala Koidz | Polysaccharide | TLR4 signaling pathway | Pre-clinical model: Healthy 1-day-old Magang goslings | [117] |
16 | Eucommia ulmoides Oliv | Polysaccharide | Decline in ALT, AST, MDA, SOD values | Pre-clinical model: Kunming clean grade, 60 mice, weight (8 weeks old 21 ± 4) g, half male and half male | [118] |
17 | Ostrea plicatula Gmelin | Crude polysaccharide | Activation the Nrf2-ARE pathway and anti-oxidative stress | Pre-clinical model: Male BALB/c mice, (6Â weeks old) | [119] |
18 | Phellinus linteus | Polysaccharide | Anti-oxidative | Pre-clinical model: Kunming female mice (5 weeks old, 22–30 g) | [120] |
19 | Polygonatum sibiricum | Crude polysaccharide | Anti-oxidative | Pre-clinical model: 40 clean-grade SD rats, half male and half male, (160–180 g) | [97] |
20 | Cordyceps militaris link | Polysaccharide | Anti-oxidative | Pre-clinical model: ICR male mice (30 ± 2 g) | [121] |
21 | Cordyceps cicadae | Polysaccharide | Anti-oxidative, scavenging free radicals | Pre-clinical model: Kunming mice (20 ± 2 g) | [122] |
22 | Sagittaria Sagittifolia L | Polysaccharide | Inhibition on CYP2E1 and CYP3A4 | Pre-clinical model: Human HepG 2 cell | [123] |
23 | Pinus koraiensis Sieb. et Zucc | Polysaccharide | Improving hepatic antioxidant capacity via NRF2/ARE pathway and regulating inflammation response | Pre-clinical model: Mail SPF Kunming mice (20–22 g) | [124] |
24 | Seaweed | Polysaccharide | Up-regulate the expression of Ntcp | Pre-clinical model: Wistar male rat (200–220 g) | [125] |
25 | Hippophae rhamnoides Linn | Polysaccharide | Suppressed the expression of TLR4 and p-JNK | Pre-clinical model: Male C57BL/6 mice (8Â weeks old) | [126] |
26 | Astragalus membranaceus var. mongholicus | Polysaccharide | Anti-oxidative | Pre-clinical model: SD SPF rat, grade, for both sexes (200–220 g) | [127] |
27 | Panar japonicas C.A. Mey | Neutral polysaccharide (70.61%); uronic acid (15.89%) | Anti-oxidative and anti-inflammatory | Pre-clinical model: Kunming SPF male mice (20–22 g) | [128] |
28 | Dendrobium officinale Kimura et Migo | Polysaccharide | Suppressing the oxidative stress and activating the Nrf2 − Keap1 signaling pathway | Pre-clinical model: Male ICR mice (6–8 weeks old) | [129] |
29 | Inonotus obliquus | Polysaccharide (98%) | Anti-oxidative | Pre-clinical model: 40 clean-grade mice (20–25 g) | [130] |
30 | Poria cocos | Polysaccharide | Suppressing inflammatory response and apoptosis in liver cells | Pre-clinical model: Male Kunming mice (6–7 weeks old, 18–22 g) | [131] |
31 | Schisandra chinensis (Turcz) Baill | Polysaccharide | Inhibition of hepatocyte apoptosis | Pre-clinical model: ICR male mice (19–22 g) | [132] |
32 | Pleurotus citrinopileatus Sing | Polysaccharide | Regulate activity of CYP2E1 and CYP3A | Pre-clinical model: KM mouse, half male and half female (20–22 g) | [133] |
33 | Morus alba L. | Total polysaccharides | Anti-oxidative and anti-inflammation | Pre-clinical model: Kunming SPF male (8 weeks old, 18–23 g) | [134] |
34 | Atractylodes chinensis (DC.) Koidz | Polysaccharide | Reduce transaminase activity, lower ALT, AST | Pre-clinical model: KM male mice (27–30 g) | [135] |